Immunomedics (IMMU) Announces Objective Response Data for IMMU-132
Tweet Send to a Friend
Immunomedics, Inc., (Nasdaq: IMMU) today reported that 71% of patients (34 of 48) with diverse metastatic solid cancers had durable ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE